EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

Ryan J Jalleh, Nicholas J Talley, Michael Horowitz, Michael A Nauck

Journal of Clinical Investigation · 16.02.2026 · 136 (4)

DOI: 10.1172/jci194740 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.02.2026. Verfasst von Ryan J Jalleh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GLP-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes (T2D) and obesity, with robust evidence for cardiovascular and renal benefits. Nevertheless, GLP-1RA therapy is associated with a pattern of adverse events affecting their safety and tolerability. Here, we delineate mechanisms potentially leading to adverse responses to GLP-1RAs, describe the impact of side effects on treatment persistence, discuss potential mitigation strategies, and identify areas requiring further studies. Concerns that GLP-1RAs raise the risk for acute pancreatitis and pancreatic cancer have been dispelled by long-term clinical trials. However, GLP-1RAs may confer an increased risk for thyroid cancer. Sight-threatening eye complications resulting from rapid reductions in glycemia may be avoided by retinal screening and ophthalmologic treatment before GLP-1RA initiation. The slowing of gastric emptying with GLP-1RA treatment increases the propensity for retained gastric contents, which could increase the risk of aspiration during upper gastrointestinal endoscopy or general anesthesia. These risks may, however, be elevated in individuals with long-standing T2D even in the absence of GLP-1RA treatment. Improved pharmacovigilance and a more standardized, quantitative assessment of adverse events in clinical trials, particularly in the assessment of gastrointestinal symptoms, would facilitate definition of the benefit-risk relationship for individual medications and indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2ObesityHypoglycemic AgentsHumansPancreatitisGlucagon-Like Peptide-1 ReceptorAnimalsPancreatic NeoplasmsGastric Emptying

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorGLP1R protein, human

Autor:innen und Institutionen

  • Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
  • Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
  • School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
  • Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, Sankt Josef-Hospital, Ruhr-University, Bochum, Germany.
  • Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.

Zitieren

APA

Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026). The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. Journal of Clinical Investigation, 136(4). https://doi.org/10.1172/jci194740

Vancouver

Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. Journal of Clinical Investigation. 2026;136(4). doi:10.1172/jci194740

BibTeX
@article{Jalleh2026,
  author = {Jalleh, Ryan J and Talley, Nicholas J and Horowitz, Michael and Nauck, Michael A},
  title = {The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {4},
  doi = {10.1172/jci194740}
}
Kostenlos starten →